Supernus Pharmaceuticals Enters Asset Purchase Agreement with Navitor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SUPN?
Source: seekingalpha
- Asset Purchase Agreement: Supernus Pharmaceuticals has entered into an asset purchase agreement with Navitor Pharmaceuticals effective April 1, 2026, with a potential total payment of up to $350 million contingent on specific development, regulatory, and commercial achievements, highlighting the company's commitment to drug development.
- Milestone Payment Commitment: The agreement requires Supernus to complete a Phase 2b clinical study and make milestone payments totaling up to $350 million upon achieving specific milestones, reflecting the company's confidence in product success and strategic positioning in a competitive pharmaceutical market.
- Non-Competition Clause: The agreement includes a five-year non-competition and non-solicitation covenant to protect Supernus's business interests, ensuring that post-acquisition, the company will not face interference from competitors, thereby strengthening its market position.
- Clinical Research Risk: Should the Phase 2 study fail, Supernus is not obligated to continue with the milestones or commercialization efforts, emphasizing the critical nature of clinical research success for the company's future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SUPN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SUPN
Wall Street analysts forecast SUPN stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 50.540
Low
55.00
Averages
61.33
High
65.00
Current: 50.540
Low
55.00
Averages
61.33
High
65.00
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SUPERNUS PHARMACEUTICALS INC ACQUIRES ASSETS FOR NV-5138 OR SPN-820, INCLUDING INTELLECTUAL PROPERTY AND INVENTORY - SEC FILING
Asset Acquisition: Supernus Pharmaceuticals is set to acquire assets related to the NV-5138 or SPN-820, which includes inventory and intellectual property.
Filing Details: The acquisition process involves a SEC filing, indicating regulatory compliance and transparency in the transaction.
See More
Supernus Pharmaceuticals Enters Asset Purchase Agreement with Navitor
- Asset Purchase Agreement: Supernus Pharmaceuticals has entered into an asset purchase agreement with Navitor Pharmaceuticals effective April 1, 2026, with a potential total payment of up to $350 million contingent on specific development, regulatory, and commercial achievements, highlighting the company's commitment to drug development.
- Milestone Payment Commitment: The agreement requires Supernus to complete a Phase 2b clinical study and make milestone payments totaling up to $350 million upon achieving specific milestones, reflecting the company's confidence in product success and strategic positioning in a competitive pharmaceutical market.
- Non-Competition Clause: The agreement includes a five-year non-competition and non-solicitation covenant to protect Supernus's business interests, ensuring that post-acquisition, the company will not face interference from competitors, thereby strengthening its market position.
- Clinical Research Risk: Should the Phase 2 study fail, Supernus is not obligated to continue with the milestones or commercialization efforts, emphasizing the critical nature of clinical research success for the company's future growth.
See More
Supernus Executive Sells 107,250 Shares of Stock
- Executive Stock Sale: Padmanabh P. Bhatt, Senior VP at Supernus Pharmaceuticals, sold 107,250 shares of common stock from March 16 to 18, 2026, for approximately $5.4 million, indicating a significant shift in his stock holdings within the company.
- Impact on Holdings: Following this transaction, Bhatt's direct common stock ownership dropped to 17,044 shares; however, he retains 39,500 Employee Stock Options, which could enhance his future equity exposure in the company.
- Company Financial Performance: Supernus reported $719 million in revenue for the fiscal year 2025, a 9% year-over-year increase, with growth products contributing $521.8 million, showcasing the company's ongoing expansion in the CNS drug market, despite a net loss of $38.6 million due to rising acquisition and commercialization costs.
- Market Reaction and Investor Focus: Bhatt's stock sale was executed under a prearranged Rule 10b5-1 plan adopted in December, and with shares up about 53% over the past year, this transaction does not raise red flags, instead reflecting normal selling behavior during a strong performance period.
See More
Supernus Pharmaceuticals Reports Q4 2025 Results and 2026 Guidance
- Revenue Growth: In Q4 2025, Supernus reported total revenue of $211.6 million, a 21% increase from $174.2 million in Q4 2024, indicating strong market acceptance of newer therapies despite declines in legacy product sales.
- Increased Operating Loss: The company faced an operating loss of $3.9 million in Q4 2025, a stark contrast to operating earnings of $21.4 million in Q4 2024, primarily due to rising SG&A acquisition-related costs, highlighting financial pressures during expansion.
- Annual Performance Review: For the full year 2025, total revenues reached $719 million, up 9%, but the operating loss widened to $62.3 million, impacted by $72.9 million in acquisition costs related to Sage Therapeutics, reflecting short-term financial challenges from its acquisition strategy.
- 2026 Outlook: Supernus projects total revenues of $840 million to $870 million for 2026, with operating earnings expected to rebound to between $0 million and $30 million, indicating confidence in future market performance despite ongoing adjustments in profitability.
See More
Supernus Pharmaceuticals Reports Record Q4 2025 Earnings and Strategic Progress
- Record Revenue: Supernus Pharmaceuticals achieved total revenue of $211.6 million in Q4 2025, a 21% increase year-over-year, with net product sales reaching $158.1 million, indicating robust performance in core products, particularly Qelbree and GOCOVRI.
- Significant Product Growth: The four growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—accounted for approximately 76% of total revenue in Q4, with ONAPGO's net sales rising from $6.8 million in Q3 to $8.9 million, reflecting strong market demand and resolution of supply issues.
- Optimistic Outlook: Management projects total revenues for 2026 to range from $840 million to $870 million, with ONAPGO net sales expected between $45 million and $70 million, demonstrating confidence in future growth while maintaining a strong cash flow and debt-free financial position.
- R&D and Integration Focus: Supernus completed the acquisition of Sage Therapeutics and plans to retain some assets for internal development, emphasizing the company's strategic priority on R&D and product portfolio integration to drive long-term growth.
See More
Supernus Pharmaceuticals Reports Strong Q4 2025 Earnings and Revenue Growth
- Significant Revenue Growth: Supernus Pharmaceuticals reported $211.57 million in revenue for Q4 2025, reflecting a 21.5% year-over-year increase and surpassing the market expectation of $196.69 million, indicating strong market performance.
- Earnings Per Share Beat: The EPS for the quarter was $0.92, up 22.7% from $0.75 a year ago, and significantly exceeding the consensus estimate of $0.28, showcasing a notable improvement in the company's profitability.
- Positive Market Reaction: With both revenue and EPS exceeding expectations, investor sentiment towards Supernus is optimistic, likely driving stock price appreciation and reflecting confidence in the company's continued growth potential.
- Key Metrics Insight: Analysts emphasize that while revenue and earnings are focal points for investors, the performance of other key metrics provides deeper insights into the company's future stock price trajectory, aiding investors in making more informed decisions.
See More
SUPERNUS PHARMACEUTICALS INC ACQUIRES ASSETS FOR NV-5138 OR SPN-820, INCLUDING INTELLECTUAL PROPERTY AND INVENTORY - SEC FILING
Asset Acquisition: Supernus Pharmaceuticals is set to acquire assets related to the NV-5138 or SPN-820, which includes inventory and intellectual property.
Filing Details: The acquisition process involves a SEC filing, indicating regulatory compliance and transparency in the transaction.
See More
Supernus Pharmaceuticals Enters Asset Purchase Agreement with Navitor
- Asset Purchase Agreement: Supernus Pharmaceuticals has entered into an asset purchase agreement with Navitor Pharmaceuticals effective April 1, 2026, with a potential total payment of up to $350 million contingent on specific development, regulatory, and commercial achievements, highlighting the company's commitment to drug development.
- Milestone Payment Commitment: The agreement requires Supernus to complete a Phase 2b clinical study and make milestone payments totaling up to $350 million upon achieving specific milestones, reflecting the company's confidence in product success and strategic positioning in a competitive pharmaceutical market.
- Non-Competition Clause: The agreement includes a five-year non-competition and non-solicitation covenant to protect Supernus's business interests, ensuring that post-acquisition, the company will not face interference from competitors, thereby strengthening its market position.
- Clinical Research Risk: Should the Phase 2 study fail, Supernus is not obligated to continue with the milestones or commercialization efforts, emphasizing the critical nature of clinical research success for the company's future growth.
See More
Supernus Executive Sells 107,250 Shares of Stock
- Executive Stock Sale: Padmanabh P. Bhatt, Senior VP at Supernus Pharmaceuticals, sold 107,250 shares of common stock from March 16 to 18, 2026, for approximately $5.4 million, indicating a significant shift in his stock holdings within the company.
- Impact on Holdings: Following this transaction, Bhatt's direct common stock ownership dropped to 17,044 shares; however, he retains 39,500 Employee Stock Options, which could enhance his future equity exposure in the company.
- Company Financial Performance: Supernus reported $719 million in revenue for the fiscal year 2025, a 9% year-over-year increase, with growth products contributing $521.8 million, showcasing the company's ongoing expansion in the CNS drug market, despite a net loss of $38.6 million due to rising acquisition and commercialization costs.
- Market Reaction and Investor Focus: Bhatt's stock sale was executed under a prearranged Rule 10b5-1 plan adopted in December, and with shares up about 53% over the past year, this transaction does not raise red flags, instead reflecting normal selling behavior during a strong performance period.
See More
Supernus Pharmaceuticals Reports Q4 2025 Results and 2026 Guidance
- Revenue Growth: In Q4 2025, Supernus reported total revenue of $211.6 million, a 21% increase from $174.2 million in Q4 2024, indicating strong market acceptance of newer therapies despite declines in legacy product sales.
- Increased Operating Loss: The company faced an operating loss of $3.9 million in Q4 2025, a stark contrast to operating earnings of $21.4 million in Q4 2024, primarily due to rising SG&A acquisition-related costs, highlighting financial pressures during expansion.
- Annual Performance Review: For the full year 2025, total revenues reached $719 million, up 9%, but the operating loss widened to $62.3 million, impacted by $72.9 million in acquisition costs related to Sage Therapeutics, reflecting short-term financial challenges from its acquisition strategy.
- 2026 Outlook: Supernus projects total revenues of $840 million to $870 million for 2026, with operating earnings expected to rebound to between $0 million and $30 million, indicating confidence in future market performance despite ongoing adjustments in profitability.
See More
Supernus Pharmaceuticals Reports Record Q4 2025 Earnings and Strategic Progress
- Record Revenue: Supernus Pharmaceuticals achieved total revenue of $211.6 million in Q4 2025, a 21% increase year-over-year, with net product sales reaching $158.1 million, indicating robust performance in core products, particularly Qelbree and GOCOVRI.
- Significant Product Growth: The four growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—accounted for approximately 76% of total revenue in Q4, with ONAPGO's net sales rising from $6.8 million in Q3 to $8.9 million, reflecting strong market demand and resolution of supply issues.
- Optimistic Outlook: Management projects total revenues for 2026 to range from $840 million to $870 million, with ONAPGO net sales expected between $45 million and $70 million, demonstrating confidence in future growth while maintaining a strong cash flow and debt-free financial position.
- R&D and Integration Focus: Supernus completed the acquisition of Sage Therapeutics and plans to retain some assets for internal development, emphasizing the company's strategic priority on R&D and product portfolio integration to drive long-term growth.
See More
Supernus Pharmaceuticals Reports Strong Q4 2025 Earnings and Revenue Growth
- Significant Revenue Growth: Supernus Pharmaceuticals reported $211.57 million in revenue for Q4 2025, reflecting a 21.5% year-over-year increase and surpassing the market expectation of $196.69 million, indicating strong market performance.
- Earnings Per Share Beat: The EPS for the quarter was $0.92, up 22.7% from $0.75 a year ago, and significantly exceeding the consensus estimate of $0.28, showcasing a notable improvement in the company's profitability.
- Positive Market Reaction: With both revenue and EPS exceeding expectations, investor sentiment towards Supernus is optimistic, likely driving stock price appreciation and reflecting confidence in the company's continued growth potential.
- Key Metrics Insight: Analysts emphasize that while revenue and earnings are focal points for investors, the performance of other key metrics provides deeper insights into the company's future stock price trajectory, aiding investors in making more informed decisions.
See More
